research Intramuscular triamcinolone acetonide: An undervalued option for refractory alopecia areata
Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.
Search
forProducts matching "scalp alopecia areata"
Tracking 1 products like 217 Hair Tonic 15% (Oil Base) from by companies like ZeeMoreUncle. View product »
Sort by
Research
900-930 / 1000+ resultsresearch Evidence-based treatment of alopecia areata
Topical 5% minoxidil lacks strong evidence for treating alopecia areata.
research Ensemble of pre-learned deep learning model and an optimized LSTM for Alopecia Areata classification
The new model improves Alopecia Areata classification accuracy to 93.1%.
research Alopecia areata in a patient with psoriatic arthritis and C rohn's disease receiving etanercept
Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
research Concomitant presentation of alopecia areata in siblings: A rare occurrence
Two siblings both had a rare case of alopecia areata at the same time.
research Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review
Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.
research Triamcinolone Acetonide Mesotherapy in the Treatment of Recalcitrant Patches of Alopecia Areata - A Pilot Study
Triamcinolone acetonide mesotherapy may be effective for treating patchy hair loss in alopecia areata.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Case of alopecia induced by sorafenib, possible mechanism similar to alopecia areata
Sorafenib may cause hair loss in a way similar to alopecia areata.
research Clinical and Histopathological Features of Itch in Patients with Alopecia Areata
Some patients with Alopecia Areata experience itch due to immune cells and enzymes that cause itching.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
research Twenty‐nail dystrophy and alopecia areata in an adult male with thymoma‐associated myasthenia gravis: A case report
Thymoma may link myasthenia gravis, nail dystrophy, and alopecia areata.
research Subsurface detection of hair follicles in alopecia areata using optical coherence tomography
OCT can detect hidden hair follicles in alopecia areata, indicating potential hair regrowth.
research Complete responses and SALT zero scores in alopecia areata: not the same
Significant hair regrowth doesn't always mean complete hair recovery in alopecia areata.
research 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
research 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse
Farudodstat may effectively treat alopecia areata without harming hair follicles.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research Alopecia areata: Impressive results using low-level laser therapy
Low-level laser therapy can effectively regrow hair in alopecia areata.
research Oral Baricitinib Restores Hair Loss in Alopecia Areata
Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
research 396 Vδ1 + T-cells are stress-sentinels in human skin and are implicated in alopecia areata pathogenesis
Vδ1+ T-cells in the skin contribute to hair loss in alopecia areata and could be targeted for treatment.
research 051 γδ T cells as novel players in alopecia areata pathobiology: Vδ1 + T lymphocytes may recognize “stressed” hair follicle keratinocytes, leading to IFNγ-dependent hair follicle dystrophy and immune privilege collapse
Targeting specific T cells may help treat alopecia areata.
research Clinical, Demographic and Laboratory Features of Children with Alopecia Areata
Alopecia areata severity in children is linked to atopy history, disease duration, and nail involvement, but not anemia.
research Alopecia areata.
Alopecia areata causes unpredictable hair loss and is hard to treat.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
research Exploring the Potential Links between Telogen Effluvium, Alopecia Areata, Pressure-Induced Alopecia, and General Anesthesia: A Narrative Review
General anesthesia might be linked to certain types of hair loss, but more research is needed.
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.